核心概念
Insurance denials for MRI screening impact high-risk women with BRCA mutations.
要約
Women with BRCA mutations face insurance denials for recommended MRI screenings, impacting early cancer detection. A study presented at the SGO 2023 Annual Meeting highlighted rising denial rates and the need for improved access to screenings. Key findings include denial reasons, age disparities, and the impact on cancer diagnoses.
Highlights
- BRCA mutation carriers face barriers to recommended MRI screenings.
- Rising denial rates for MRI coverage impact early cancer detection.
- Study reveals age disparities and Medicaid population impact on denials.
- Denials in 2021 increased compared to 2020, affecting patient outcomes.
- Top reasons for denials include timeframe issues and lack of medical necessity.
- Efforts to improve approval timeframe and patient resources are ongoing.
統計
"Despite guidelines supporting annual breast MRI for screening in patients with gBRCA1/2, insurance denials were present in 11% of patients."
"Compared to 2020, there were significantly more denials, and denials on appeal, in 2021."
"The lifetime breast cancer risk is 72% among BRCA1 and 69% among BRCA2 carriers."
"The cohort comprised 682 women with BRCA1/2 gene mutations who were followed in a specialized high-risk breast cancer clinic."
"The number of denials rose in 2021 but approvals remained the same; 45 breast MRIs were denied (8%); on appeal, 23 (51%) were denied, and 22 (49%) approved."
引用
"The recommendation for annual MRI screening in women at high risk for breast cancer is substantiated by many publications, including multiple prospective clinical trials."
"The American Cancer Society's Guidelines for screening breast MRI recommends annual breast MRI in women with a lifetime risk of greater than 20%."